Sclerosis multiplex (SM): vizsgálatok itt: Németország
25 of 39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 16.. Ask the study team whether a trial fits you.
- 3. fázisNot yet taking people in NémetországA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Bad Homburg, Bayreuth, Boeblingen, Dresden, Essen, Hamburg, Leipzig, Mainz, Neuburgan der Donau, Trier, Ulm
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - 1/2. fázisNot yet taking people in NémetországAn Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
- Where
- Tuebingen
- Életkor
- 18 év to 80 év
- People
- 36
- Run by
- University Hospital Tuebingen
See details and how to joinNCT07932262 · EU 2024-519491-60-00 - 1. fázisNot yet taking people in NémetországImmune Cell Therapy for People with Early, Active Multiple Sclerosis
- Where
- Hanover
- Életkor
- 18 év and over
- People
- 10
- Run by
- Medizinische Hochschule Hannover
See details and how to join2025-522409-39-00 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Bad Homburg, Bayreuth, Boeblingen, Dresden, Erbach, Essen, Hamburg, Heidelberg, Jena, Leipzig, Mainz, Muenster, Regensburg, Trier, Ulm
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 2. fázisTaking peopleStudy to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
- Where
- Bielefeld, Bochum, Dresden, Jena, Kassel, Muenster, Siegen, Wuerzburg
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Celgene Corp.
See details and how to join2024-517745-14-00 - 3. fázisFut, nem toborozEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Bochum, Dresden, Duesseldorf, Leipzig, Ulm
- Életkor
- 18 év to 64 év
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 - 3. fázisTaking peopleAn Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
- Where
- Bremen, Ulm, Wiesbaden
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06675955 · EU 2023-507633-21-01 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Where
- Bielefeld, Bochum, Dresden, Essen, Jena, Kassel, Meisenheim, Münster, Siegen, Würzburg
- Életkor
- 18 év to 70 év
- People
- 200 worldwide
- Run by
- Celgene
See details and how to joinNCT06782490 - No phaseNot yet taking people in NémetországEvaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
- Where
- Ulm
- Életkor
- 18 év to 70 év
- People
- 100 worldwide
- Run by
- Otto Bock Healthcare Products GmbH
See details and how to joinNCT07897760 - 3. fázisTaking peopleEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Where
- Berlin, Bochum, Erbach, Essen, Greifswald, Heidelberg, Marburg, Muenster, Regensburg, Ulm
- Életkor
- 40 év to 70 év
- People
- 400 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00 - 2. fázisTaking peopleMulticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
- Where
- Cologne, Dresden, Duesseldorf, Erbach, Greifswald, Hamburg
- Életkor
- 18 év to 64 év
- People
- 230 worldwide
- Run by
- Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00 - 3. fázisFut, nem toborozA Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
- Where
- Dresden, Leipzig, Unterhaching
- Életkor
- 18 év to 64 év
- People
- 125 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-512914-16-00 - 2. fázisNot yet taking people in NémetországA Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
- Where
- Datteln, Dresden
- Életkor
- 10 év to 17 év
- People
- 25 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07503340 · EU 2025-524164-37-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Cottbus, Erbach im Odenwald, Erfurt, Freiburg im Breisgau, Giessen, Greifswald, Halle, Heidelberg, Ibbenbueren, Itzehoe, Jena, Leipzig, Mannheim, Munich, Tübingen, Ulm, Unterhaching, Wiesbaden
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisNot yet taking people in NémetországNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Berlin, Bielefeld, Bochum, Boeblingen, Dresden, Duesseldorf, Erbach, Essen, Giessen, Jena, Leipzig, Muenster, Ulm
- Életkor
- 18 év to 60 év
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - 2. fázisTaking peopleA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
- Where
- Berlin, Bochum, Bonn, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Leipzig, Mannheim, Muenster, Munich, Tuebingen, Ulm
- Életkor
- 18 év to 60 év
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00 - 3. fázisFut, nem toborozEfficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
- Where
- Bochum, Freiburg im Breisgau, Goettingen
- Életkor
- Up to 17 év
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-511686-11-00 - 1/2. fázisTaking peopleMB-CART2019.1 in refractory MS
- Where
- Berlin, Hamburg
- Életkor
- 18 év and over
- People
- 25
- Run by
- Miltenyi Biomedicine GmbH
See details and how to join2024-517601-82-00 - 1. fázisVisszavonvaAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis
- Where
- Leipzig, Magdeburg, Würzburg
- Életkor
- 18 év to 60 év
- People
- 24 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07224373 - 3. fázisTaking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Cottbus, Erbach, Erfurt, Freiburg im Breisgau, Giessen, Greifswald, Halle (saale), Heidelberg, Ibbenbueren, Itzehoe, Jena, Leipzig, Mannheim, Munich, Tuebingen, Ulm, Unterhaching, Wiesbaden, Wuerzburg
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 - 1/2. fázisTaking peopleMB-CART2019.1 in Refractory Multiple Sclerosis
- Where
- Berlin
- Életkor
- 18 év to 55 év
- People
- 26
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT07178431 - No phaseTaking peopleNon-invasive Brain Stimulation in Multiple Sclerosis Fatigue
- Where
- Berlin
- Életkor
- 18 év to 70 év
- People
- 84
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07438964 - No phaseCsak meghívásosClinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
- Where
- Berlin, Bochum, Dresden
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- icometrix
See details and how to joinNCT07032246 - No phaseTaking peopleStimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction
- Where
- Berlin
- Életkor
- 18 év to 60 év
- People
- 150
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07183683 - No phaseTaking peopleLight Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis
- Where
- Munich
- Életkor
- 18 év to 60 év
- People
- 50
- Run by
- Technical University of Munich
See details and how to joinNCT06389968